CD276 is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 5 are open and 2 are closed. Of the trials that contain CD276 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 4 clinical trials for melanoma, of which 2 are open and 2 are closed. Of the trials that contain CD276 status and melanoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CD276 status and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) [4].

CD276 is an inclusion criterion in 3 clinical trials for desmoplastic small round cell tumor, of which 2 are open and 1 is closed. Of the trials that contain CD276 status and desmoplastic small round cell tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 3 clinical trials for neuroblastoma, of which 2 are open and 1 is closed. Of the trials that contain CD276 status and neuroblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CD276 status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (1 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CD276 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 1 is open and 1 is closed. Of the trials that contain CD276 status and osteosarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for primitive neuroectodermal tumor, of which 1 is open and 1 is closed. Of the trials that contain CD276 status and primitive neuroectodermal tumor as inclusion criteria, 2 are phase 1 (1 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CD276 status and prostate carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CD276 status and renal cell carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain CD276 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for rhabdomyosarcoma, of which 1 is open and 1 is closed. Of the trials that contain CD276 status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 2 clinical trials for Wilms tumor, of which 1 is open and 1 is closed. Of the trials that contain CD276 status and Wilms tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for Ewing sarcoma/peripheral primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and Ewing sarcoma/peripheral primitive neuroectodermal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for malignant leptomeningeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and malignant leptomeningeal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD276 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD276 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CD276 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].